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ultiple, Brief Coronary Occlusions
uring Early Reperfusion Protect Rabbit
earts by Targeting Cell Signaling Pathways
i-Ming Yang, MD, PHD,* J. Bradley Proctor, BS,* Lin Cui, MD,* Thomas Krieg, MD,*
ames M. Downey, PHD,* Michael V. Cohen, MD, FACC*†
obile, Alabama
OBJECTIVES An in situ model was used to test whether and how multiple occlusions at reperfusion can
protect rabbit myocardium.
BACKGROUND Recently it was demonstrated that postconditioning in dogs salvaged ischemic myocardium.
METHODS Control hearts underwent 30-min regional ischemia/3-h reperfusion, whereas in experimen-
tal hearts four postconditioning cycles of 30-s occlusion/30-s reperfusion starting 30 s after
release of the index coronary occlusion were added in the presence or absence of various cell
signaling antagonists.
RESULTS Postconditioning decreased infarction from 35.4  2.7% of the risk zone in control hearts to
19.8  1.8% (p  0.05). Six cycles did not result in greater protection. If postconditioning
cycles were begun after 10 min of reperfusion, protection was no longer evident. Either the
non-selective KATP channel closer glibenclamide or the putatively selective mitochondrial
KATP channel antagonist 5-hydroxydecanoate administered 5 min before reperfusion blocked
the protection afforded by postconditioning, indicating involvement of the mitochondrial
KATP channel. PD98059, a mitogen-activated protein/extracellular-signal regulated kinase
(MEK) 1/2 and therefore extracellular-signal regulated kinase (ERK) inhibitor, and N-
nitro-L-arginine methyl ester, an antagonist of nitric oxide synthase, infused shortly before
reperfusion also aborted the protection afforded by postconditioning. Combined ischemic
postconditioning and preconditioning resulted in significantly greater protection than either
alone.
CONCLUSIONS Multiple, short, regional coronary occlusions immediately after prolonged myocardial
ischemia are an effective cardioprotective intervention in the rabbit, and the mechanism of
protection involves activation of ERK, production of nitric oxide, and opening of mitochon-
drial KATP channels. These observations suggest that a similar approach could be applied in
the cardiac catheterization laboratory to protect reperfused myocardium after primary
angioplasty in patients with acute myocardial infarction. (J Am Coll Cardiol 2004;44:
1103–10) © 2004 by the American College of Cardiology Foundationt
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eschemic preconditioning is acknowledged to be a robust
ardioprotective intervention that salvages ischemic myocar-
ium in experimental animals and probably in humans (1).
owever, as its name implies, preconditioning must be
pplied before an ischemic event to be protective, thus
imiting its utility. Ischemic preconditioning is not useful for
See page 1111
atients presenting to the hospital after onset of their
yocardial infarction. Although thrombolysis, emergency
ngioplasty, or revascularization surgery can effect reperfu-
ion with documented salvage of ischemic myocardium,
From the Departments of *Physiology and †Medicine, University of South
labama, College of Medicine, Mobile, Alabama. This study was supported in part
y grants HL-20648 and HL-50688 from the Heart, Lung, and Blood Institute of the
ational Institutes of Health.
Manuscript received March 17, 2004; revised manuscript received April 28, 2004,(ccepted May 12, 2004.hese procedures are seldom instituted early enough to
liminate infarction. Furthermore, it is thought that reper-
usion itself, although required for salvage, actually contrib-
tes to the injury (2–6). Therefore, an intervention is
eeded that can supplement the reperfusion strategy and
ttenuate reperfusion injury and/or otherwise limit necrosis
n the heart.
A pharmacologic approach has met with varying success.
he effectiveness of adenosine administered at reperfusion is
ery controversial (7–10), and we have been unable to
ocument any protection in our rabbit model (11). On the
ther hand, the adenosine A1/A2A agonist AMP579 when
dministered at reperfusion has consistently reduced infarc-
ion in all animal heart models tested (11–15). A structurally
imilar A1/A2 adenosine agonist 5=-(N-ethylcarboxamido)
denosine or NECA was equally protective, and the effect
as dependent on phosphatidylinositol 3 (PI3)-kinase,
xtracellular-signal regulated kinase (ERK), and nitric oxide
NO) (16). We recently reported that CGX-1051, a peptide
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Ischemic Postconditioning and Cardioprotection September 1, 2004:1103–10solated from the venom of the cone snail, could also salvage
yocardium when administered shortly before the onset of
eperfusion (17). Several other agents appear to be protec-
ive when given to isolated heart models. These include
radykinin (18), cardiotrophin-1 (19), insulin (20), and
ransforming growth factor-beta-1 (21). Protection with
hese compounds is generally dependent on PI3-kinase and
RK. However, none of these agents has been validated in
n in situ model, which would be required before clinical
esting could be considered.
Very recently Zhao et al. reported a most improbable
bservation (22). They noted that several brief coronary
cclusions after a 60-min occlusion in dogs significantly
educed infarct size. This postconditioning protocol has
linical appeal. Because urgent angioplasty is rapidly becom-
ng the principal reperfusion treatment for acute myocardial
nfarction, it would not be implausible to produce several
rief coronary occlusions immediately after the occluded
rtery is opened. Thus we wondered if ischemic postcondi-
ioning could be demonstrated in a second animal model,
ow its protection compared with that of ischemic precon-
itioning, and if elements of the signaling pathway leading
o protection were at all similar to those already documented
or pharmacologic agents that protect when infused at
eperfusion.
Abbreviations and Acronyms
ERK  extracellular-signal regulated kinase
5-HD  5-hydroxydecanoate
L-NAME  N-nitro-L-arginine methyl ester
NO  nitric oxide
NOS  nitric oxide synthase
igure 1. Experimental protocols for animal groups exposed to 30-min co
-NAME  N -nitro-L-arginine methyl ester; PC  ischemic preconditioningETHODS
ll procedures were approved by the Institutional Animal
are and Use Committee and were in accordance with
ecommendations published in the Guide for the Care and
se of Laboratory Animals (National Academic Press, Wash-
ngton, DC, 1996).
New Zealand White rabbits of either gender weighing
etween 1.5 and 2.6 kg were anesthetized with intravenous
odium pentobarbital (30 mg/kg). Throughout the experi-
ent, additional anesthesia was administered as needed (5
o 15 mg pentobarbital/15 min). A heating pad maintained
ectal temperature between 38.5°C and 39.5°C. Animals
ere intubated through a tracheotomy and ventilated with
5% O2/5% CO2 with the aid of a mechanical ventilator
MD Industries, Mobile, Alabama). Arterial pH and oxy-
en and carbon dioxide tensions were maintained within the
hysiologic range (blood gas analyzer ABL 5, Radiometer,
openhagen, Denmark). Catheters filled with heparinized
aline (10 U/ml) were placed into the left carotid artery to
onitor arterial blood pressure and to withdraw blood
amples and into the right jugular vein to administer drugs.
fter left thoracotomy, a major branch of the left coronary
rtery was surrounded with a suture to form a snare. The
abbits were allowed to stabilize for 20 min after surgery
efore the protocols were begun.
rotocols. Hearts of 13 experimental groups experienced 30
in of regional ischemia (Fig. 1), whereas hearts of four other
roups experienced 45 min of regional ischemia (Fig. 2). In all
earts, reperfusion after the occlusion lasted for 3 h. Control
earts had only this occlusion and reperfusion. For ischemically
reconditioned rabbits, 5-min occlusion/10-min reperfusion
mmediately preceded the long ischemia. In postconditioning
y artery occlusions. Glib  glibenclamide; 5-HD  5-hydroxydecanoate;ronar
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September 1, 2004:1103–10 Ischemic Postconditioning and Cardioprotectionabbits, four or six cycles of 30-s occlusion/30-s reperfusion
tarted 30 s after release of the indicated long ischemia. All
rugs, glibenclamide (0.3 mg/kg), 5-hydroxydecanoate (5-
D) (5 mg/kg), PD98059 (0.3 mg/kg), and N-nitro-L-
rginine methyl ester (L-NAME) (10 mg/kg), were given as
ntravenous boluses just 5 min before the onset of reperfusion.
hese doses have previously been used by us (17) and others
23–26) to selectively block the target. In four additional
roups, each of these four tool drugs was infused alone just
efore reperfusion in the absence of any postconditioning
timulus to determine the effect of the drugs themselves. In one
ast group, four cycles delayed, the postconditioning cycles were
elayed for 10 min after the onset of reperfusion.
isk zone and infarct size. After completion of studies, all
earts were excised, suspended by the aortic root from a
angendorff apparatus, and perfused with 0.9% saline. The
oronary snare was retightened, and 2- to 9-m fluorescent
icrospheres (Duke Scientific, Palo Alto, California) were
nfused to delineate the area at risk as the nonfluorescent
egion. Hearts were frozen, cut into 2-mm transverse slices,
ncubated for 20 min in 1% triphenyltetrazolium chloride
pH 7.4, 37°C), and then immersed in 10% formalin. The
orders between fluorescent and nonfluorescent regions
ere marked under ultraviolet light to identify the risk zone.
nfarct and risk zone areas were planimetered, and volumes
alculated. Infarct size is presented as a percent of risk zone.
aterials. All drugs were obtained from Sigma Chemical
o. (St. Louis, Missouri). Glibenclamide and PD98059
ere dissolved in dimethyl sulfoxide. The 5-HD and
-NAME were dissolved in 0.9% saline.
tatistics. Data are expressed as mean  SEM. One-way
nalysis of variance combined with Tukey’s post hoc test
as used to test for differences in infarct size and baseline
emodynamics between groups. Temporal differences in
emodynamic variables in any given group were analyzed
ith one-way repeated measures analysis of variance, and
Figure 2. Experimental protocols for animal groups exposed toukey’s post hoc test was used to examine differences Petween measurements at any given time point and baseline
bservations. Infarct sizes were plotted against risk zone
olumes for all groups, and regression lines for groups with
nterventions were compared with the regression line for the
ontrol group by analysis of covariance with Bonferroni’s
orrection for multiple comparisons. For all tests, p  0.05
as considered significant.
ESULTS
emodynamics. No differences in basal heart rate or
ystolic or diastolic pressure were noted among the experi-
ental groups (Table 1). No substantial changes in heart
ate and blood pressure were observed after administration
f drugs except for an unexpected increase in blood pressure
fter L-NAME administration in hearts destined to be
ostconditioned. Blood pressure declined modestly during
he coronary occlusion in virtually all groups, with little
ecovery during reperfusion.
nfarct size. There was no significant difference in body
eight, heart weight, or risk zone volume between the
roups (Table 2). In control hearts (30-min occlusion),
nfarct size was 35.4  2.7% of the risk zone (Fig. 3). Four
ostconditioning cycles starting 30 s after release of the
0-min coronary occlusion significantly decreased infarction
19.8 1.8%, p 0.05 vs. control). Six cycles did not result
n greater protection (19.8  1.6% infarction). However, if
our postconditioning cycles were started 10 min after
elease of the 30-min occlusion, there was no longer any
rotection (34.5 1.7% infarction). Either glibenclamide, a
on-selective adenosine triphosphate-sensitive potassium
KATP) channel closer, or 5-HD, a selective mitochondrial
ATP channel antagonist, blocked the protection of four
ycles (32.8  2.3% and 35.8  4.8% infarction, respec-
ively), indicating that the opening of mitochondrial KATP
hannels was involved in the protective mechanism (Fig. 4).
in coronary artery occlusions. PC  ischemic preconditioning.45-mD98059, a mitogen-activated protein/extracellular-signal
Table 1. Hemodynamic Data
Group
Baseline 25= Ischemia* 30= Ischemia 5=/15= Reperfusion† 30= Reperfusion
HR
(beats/
min)
SBP
(mm
Hg)
DBP
(mm
Hg)
HR
(beats/
min)
SBP
(mm
Hg)
DBP
(mm
Hg)
HR
(beats/
min)
SBP
(mm
Hg)
DBP
(mm
Hg)
HR
(beats/
min)
SBP
(mm
Hg)
DBP
(mm
Hg)
HR
(beats/
min)
SBP
(mm
Hg)
DBP
(mm
Hg)
Control 243 11 94  3 76  2 246 11 79  2‡ 61  2‡ 258  8 85  3‡ 67  4‡
4 cycles 253  4 98  2 77  3 245 9 81  3‡ 63  3‡ 247  10 77  2‡ 61  3‡ 254  0 81  3‡ 62  4‡
6 cycles 256  17 94  6 71  5 241 17 80  4‡ 59  4 235  16 76  3‡ 57  4‡ 240  15 77  4‡ 57  3‡
Glibenclamide  4 cycles 275  15 101  4 81  4 274  17 91  4‡ 70  4 268  15 92  4‡ 73  4 263  14 86  4‡ 64  4‡ 270  13 90  4‡ 67  4‡
Glibenclamide 285 10 104  5 87  4 292  2 87  6‡ 72  4 293  2 92  4‡ 72  4 298 6 95  5 75  6
5-HD  4 cycles 249  13 103  3 88  4 267  7 87  2‡ 72  1‡ 267  8 86  2‡ 70  1‡ 261  10 80  2‡ 62  3‡ 274  4 87  2‡ 68  3‡
5-HD 272  4 95  3 80  3 265  16 81  8 63  8 273  13 82  7 65  6 273 22 82  10 67  10
PD98059  4 cycles 255  8 98  2 79  2 265  7 81  5‡ 62  5‡ 261  8 80  4‡ 63  4‡ 262  10 78  5‡ 60  6‡ 258  8 84  5‡ 62  5‡
PD98059 265 13 102  2 87  2 265  13 83  4‡ 68  4‡ 268  9 90  3‡ 73  2‡ 280  8 92  2‡ 76  1‡
L-NAME  4 cycles 274 2 103  3 85  2 270  4 91  4‡ 72  4‡ 258  11 102  5 87  5 249  6 92  5‡ 76  5 245  10‡ 108  3 94  4
L-NAME 273  9 103  3 87  4 280  8 98  2 82  3 255  13 103  2 83  4 253 12‡ 110  6 95  6
4 cycles delayed 238  9 101  2 82  2 238 10 88  5‡ 69  5 268  13 87  5‡ 71  7 250  14 89  4 70  4
PC  PD98059 283 5 101  2 82  3 284 6 95  2 78  3 285  10 84  4‡ 67  5‡ 287  3 89  4‡ 74  3
Control (45=) 261 14 100  4 81  5 233 26 81  4‡ 63  3‡ 256  15 78  3‡ 58  2‡
4 cycles (45=) 223  11 97  3 80  2 228 11 74  3‡ 56  5‡ 230  11 70  3‡ 54  4‡ 231  6 75  3‡ 55  4‡
PC (45=) 262  10 104  4 83  5 254 13 78  5‡ 58  5‡ 251  13 74  4‡ 53  4‡
PC  4 cycles (45=) 256  10 100  2 78  2 246 5 88  2‡ 65  2‡ 224  7‡ 81  4‡ 59  3‡ 253  9 93  3 68  4
Values are mean  SEM. *Measurements made after 25 min of ischemia and just before tool drug administration. †Measurements made after either 5 min (all groups except 1) or 15 min (4 cycles delayed group) of reperfusion in
postconditioned groups. ‡p  0.05, statistically significant difference between experimental data and baseline.
Control (45=)  control hearts with index ischemia of 45 min; DBP  diastolic blood pressure; 5-HD  5-hydroxydecanoate; HR  heart rate; L-NAME  N-nitro-L-arginine methyl ester; PC  ischemic preconditioning; PC
(45=)  PC hearts with index ischemia of 45 min; SBP  systolic blood pressure; 4 cycles  4-cycle hearts with index ischemia of 45 min.
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September 1, 2004:1103–10 Ischemic Postconditioning and Cardioprotectionegulated kinase (MEK) 1/2 and therefore ERK inhibitor,
nd L-NAME, an antagonist of NO synthase (NOS), also
borted protection (44.8  3.1% and 45.1  2.3% infarc-
ion, respectively). For comparison, hearts preconditioned
ith ischemia were also treated with the same dose of
D98059 just before reperfusion. As seen in Figure 3, the
xpected protective effect of preconditioning was not af-
ected (13.4  3.9% infarction of the risk zone). None of
he four tool drugs administered at reperfusion had any
ndependent effect on infarct size (glibenclamide 42.2 
.2%, 5-HD 33.6  6.0%, PD98059 34.1  3.7%, and
-NAME 37.0  3.6%) (Fig. 4). Infarct sizes were plotted
gainst risk zone volumes for all groups. The regression lines
or postconditioned hearts were different from the regres-
ion line for control hearts (p  0.001), whereas there was
able 2. Infarct Size Data
Group n
Body Weight
(kg)
Heart Wei
(g)
ontrol 11 2.29  0.07 7.4 0.
cycles 10 2.35  0.07 7.4 0.
cycles 6 2.18  0.07 7.2 0.
libenclamide  4 cycles 6 2.34  0.03 7.0 0.
libenclamide 3 2.26 0.06 7.2 0.
-HD  4 cycles 6 2.30  0.04 7.0 0.
-HD 3 2.18  0.04 8.1 0.
D98059  4 cycles 6 2.28  0.07 6.8 0.
D98059 3 2.39  0.03 6.9 0.
-NAME  4 cycles 6 2.36  0.09 7.1 0.
-NAME 3 2.33  0.01 7.1 0.
cycles delayed 6 2.44  0.11 6.0 0.
C  PD98059 5 2.60  0.05 7.3 0.
ontrol (45=) 6 2.24  0.04 6.9 0.
cycles (45=) 6 2.15  0.05 6.8 0.
C (45=) 6 2.19  0.17 6.9 0.
C  4 cycles (45=) 6 2.16  0.13 6.8 0.
alues are expressed as mean  SEM. Statistical significance of difference between
n  number of animals in each group; I/R  ratio of infarct to risk zone volum
igure 3. Infarct size in in situ rabbit hearts. All animals had a 30-min
oronary occlusion and 3-h reperfusion. Open circles represent individual
xperiments, closed circles depict group means with SEM. Both four and
ix immediate postconditioning cycles protected ischemic hearts, whereas
elayed postconditioning elicited no protection. PD98059 did not blockthe protective effect of ischemic preconditioning. *p  0.05 versus control.o difference between control hearts and those postcondi-
ioned hearts also treated with either PD98059, L-NAME,
libenclamide, or 5-HD (Fig. 5).
When regional ischemia was extended to 45 min in control
earts, infarction increased to 61.7  2.2% of the risk zone
Fig. 6), and four postconditioning cycles resulted in significant
alvage (39.6  4.2% infarction, p  0.05). A single precon-
itioning cycle of 5-min occlusion/10-min reperfusion before
he 45-min ischemia also was protective (35.1  4.0% infarc-
ion, p  0.05). The combination of postconditioning and
reconditioning resulted in even greater protection than either
lone (22.5  3.1% infarction, p  0.05 vs. either ischemic
reconditioning or four cycles).
ISCUSSION
major goal of cardiovascular research is currently the
dentification of a reliable cardioprotection intervention that
an salvage ischemic myocardium. Preconditioning was
ntroduced in 1986 (27), and we know a lot about the
ignaling pathways leading to the protection afforded by
reconditioning (1,28,29), although the identity of its end-
ffector has been quite elusive. Unfortunately, the clinical
alue of preconditioning itself is limited. On the other hand,
n intervention that could be applied just before or at
eperfusion would have great clinical appeal. Although
everal pharmacologic agents that appear to limit reperfu-
ion injury have been identified (11,12,16,19–21), none of
hese is available for clinical use. The recent report about
epetitive, brief postconditioning ischemia (22), which
ould easily be produced in patients undergoing angioplasty
o open infarct arteries, again raises hope that a simple
ardioprotective intervention could produce salutary clinical
ffects.
The initial investigation by Zhao et al. (22) demonstrated
Risk Zone Volume
(cm3)
Infarct Volume
(cm3) I/R (%)
1.18 0.08 0.43 0.05 35.4  2.7
1.23 0.10 0.25 0.03 19.8 1.8*
1.09 0.12 0.22 0.04 19.8  1.6*
1.27 0.04 0.41 0.04 32.8 1.8
1.28 0.05 0.42 0.06 32.9  4.7
1.37 0.13 0.51 0.11 35.8 4.8
1.38 0.20 0.46 0.08 33.6  0.6
1.31 0.16 0.60 0.11 44.8 3.1
1.15 0.15 0.39 0.08 34.1  3.7
1.36 0.04 0.62 0.04 45.1  2.3
1.10 0.07 0.40 0.02 37.0  0.6
1.30 0.18 0.52 0.04 34.5 1.7
1.25 0.17 0.19 0.08 13.4  3.9*
1.24 0.08 0.77 0.06 61.7 2.2
1.32 0.06 0.53 0.07 39.6  4.2†
1.34 0.07 0.47 0.06† 35.1  4.0†
1.26 0.09 0.30 0.06† 22.5  3.1†
mental group and respective control group: * and †(45=) p  0.05.
er abbreviations as in Table 1.ght
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Ischemic Postconditioning and Cardioprotection September 1, 2004:1103–100 s after release of a 60-min coronary occlusion in
pen-chest dogs decreased infarction by 40%, equivalent to
he effect of preconditioning. In our rabbit model, four
ycles decreased infarction by 43%, whereas increasing the
umber of cycles did not increase the amount of salvaged
issue. We did not determine the minimum number of
ycles required to reduce infarction. However, we did note
hat the timing of this postconditioning ischemia was
ritical. If the intervention were delayed for only 10 min,
rotection was lost. Hence, in the rabbit, postconditioning
ust occur within the first 10 min of reperfusion to be
rotective. A similar observation was made for AMP579
igure 4. Infarct size in in situ rabbit hearts. All animals had a 30-mi
xperiments, closed circles depict group means with SEM. Multiple cyc
Glib), 5-hydroxydecanoate (5-HD), PD98059, and N-nitro-L-arginine m
ffect. *p  0.05 versus other groups.
igure 5. Infarct size plotted against risk zone volume for control hearts
nd hearts with four cycles of postconditioning alone or after treatment
ith either PD98059, glibenclamide (Glib), N-nitro-L-arginine methyl
ster (L-NAME), or 5-hydroxydecanoate (5-HD). Regression lines for the
ontrol group and postconditioned hearts treated with PD98059, Glib,
-NAME, or 5-HD were significantly different from that for heartsfubjected only to postconditioning (p  0.001).30) and CGX-1051 (17) when administered after reperfu-
ion.
Because ischemic postconditioning was protective, we
ondered if this protection could be added to that expected
fter ischemic preconditioning. To test for such an additive
ffect, the index ischemia was prolonged to 45 min to
ncrease infarct size in control hearts. Under these condi-
ions, both ischemic preconditioning and postconditioning
ecreased infarction from 62% to comparable levels of 35%
o 40% of the risk zone. When the same heart was subjected
o both forms of cardioprotection, infarct size declined
urther to 22%, significantly less than either preconditioning
r postconditioning alone. Because each form of cardiopro-
ection has a maximal infarct-sparing effect when applied
ingly in this protocol, their additive effect when combined
mplies that their mechanisms of action must differ. This is
urther supported by the different effects of PD98059 on the
rotection afforded by ischemic preconditioning and post-
onditioning.
This study has not uncovered the actual mechanism of
ostconditioning, However, we have identified several ele-
ents of its signal transduction pathway. Both ERK and
O are probably involved. Perhaps not surprisingly, these
lements are also thought to be involved in the signaling of
everal pharmacologic agents that appear to be protective
hen administered at reperfusion (16,18,19,21). Interest-
ngly Komalavilas et al. (31) noted that in vascular smooth
uscle cells protein kinase G activation stimulated phos-
horylation of ERK 1/2, and, of course, production of NO
y NOS leads to protein kinase G activation. Therefore,
O and ERK may be signaling elements in a common
athway. Additionally both glibenclamide and 5-HD
locked the protection of postconditioning, implying a role
onary occlusion and 3-h reperfusion. Open circles represent individual
immediate postconditioning limited infarct size, whereas glibenclamide
l ester (L-NAME) blocked their protection. The tool drugs alone had non cor
les of
ethyor mitochondrial KATP channels. The protection of CGX-
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September 1, 2004:1103–10 Ischemic Postconditioning and Cardioprotection051 that was found to limit infarction in the in situ rabbit
eart when given at reperfusion was also dependent on
itochondrial KATP channels (17). Possible involvement of
hese channels in the protection of other reperfusion agents
as not been investigated. Triggering of preconditioning
epends on the production of reactive oxygen species by
itochondria after generation of NO and the opening of
itochondrial KATP channels (29). Thus there are some
arallels between preconditioning and postconditioning.
owever, ERK is not part of preconditioning’s signaling
32), as again shown in this study.
Thus, the protection afforded by postconditioning has
ow been observed in two animal models—dog and rabbit.
he timing of the intervention is critical, and its protection
an be added to that of preconditioning. The mechanism of
he protection is uncertain. It is not yet known if ion fluxes
r mitochondrial or cell swelling is affected. An initial report
uggests that postconditioning reduces superoxide produc-
ion by reperfused myocardium (22), but we do not know if
hat is the cause or the result of the protection. This report
ot only has confirmed the efficacy of postconditioning but
lso has revealed that its protection is dependent on cellular
ignal transduction pathways. In fact, most of these critical
ignaling entities are also involved in preconditioning.
erhaps more notable, other pharmacologic agents success-
ul at protecting ischemic myocardium when administered
t reperfusion use these same pathways leading to activation
f the final effector.
This procedure of postconditioning could be safely and
eadily adapted for clinical use. After initial reperfusion of
he infarct artery during primary angioplasty in a patient
ith an acute myocardial infarction, several brief, low-
ressure balloon occlusions of the vessel could be performed
igure 6. Infarct size in in situ rabbit hearts. All animals had a 45-mi
xperiments, closed circles depict group means with SEM. Four postcondi
f 5-min occlusion/10-min reperfusion before the 45-min ischemia also was
esulted in even greater protection than either alone. *p  0.05 versus conefore the procedure is completed with subsequent addi-ional dilations to obtain grade 3 Thrombolysis In Myocar-
ial Infarction (TIMI) flow and stenting if required. Cur-
ent catheterization laboratory protocols would not be
xpected to routinely postcondition the heart, because of the
ritical requirement for multiple, brief occlusions in the first
econds of reperfusion. This approach has important clinical
otential and should be further explored.
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